Myacyne
Brand names,
Myacyne
Analogs
Myacyne
Brand Names Mixture
Myacyne
Chemical_Formula
C23H46N6O13
Myacyne
RX_link
http://www.rxlist.com/cgi/generic3/neomy.htm
Myacyne
fda sheet
Myacyne
msds (material safety sheet)
Myacyne
Synthesis Reference
No information avaliable
Myacyne
Molecular Weight
614.644 g/mol
Myacyne
Melting Point
6 mg/mL (as sulfate form)
Myacyne
H2O Solubility
No information avaliable
Myacyne
State
Solid
Myacyne
LogP
-9.895
Myacyne
Dosage Forms
Powder
Myacyne
Indication
For the adjunctive treatment of acute hepatic failure, alcoholic cirrhosis of the liver, and suppression of intestinal bacteria.
Myacyne
Pharmacology
Neomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.
Myacyne
Absorption
Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin is absorbed through intact intestinal mucosa, significant amounts may be absorbed through ulcerated or denuded mucosa or if inflammation is present.
Myacyne
side effects and Toxicity
LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce neurotoxicity, ototoxicity and/or nephrotoxicity.
Myacyne
Patient Information
Before administering the drug, patients or members of their families should be informed of possible toxic effects
on the eighth nerve. The possibility of acute toxicity increases in premature infants and neonates.
Myacyne
Organisms Affected
Enteric bacteria and other eubacteria